<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04531033</url>
  </required_header>
  <id_info>
    <org_study_id>LF-1</org_study_id>
    <nct_id>NCT04531033</nct_id>
  </id_info>
  <brief_title>Does Daily Supplementation of Lactobacillus Acidophilus MPH734, for One Week, Affect Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo</brief_title>
  <acronym>LF</acronym>
  <official_title>Does Daily Supplementation of Lactobacillus Acidophilus MPH734 (Lacto-FreedomTM, or LF), for One Week, Affects Acute (Immediate), Subacute (7 Days), and Post-treatment Discontinuation (30-, 60-, and 90- Day) Lactose Metabolism, Gastrointestinal Symptoms, and Clinical Markers of Inflammation and Safety Compared to a Placebo?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lemuel W. Taylor IV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manzo Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Mary Hardin-Baylor</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if twice or three times daily supplementation of&#xD;
      Lactobacillus acidophilus MPH734 (Lacto-FreedomTM, or LF), for one week, affects acute&#xD;
      (immediate), subacute (7 days), and post-treatment discontinuation (30-, 60-, and 90- day)&#xD;
      lactose metabolism, gastrointestinal symptoms, and clinical markers of inflammation and&#xD;
      safety compared to a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be included and/or excluded in the study based on the criteria below:&#xD;
&#xD;
      Inclusion Criteria&#xD;
&#xD;
        -  Participants will be male or female between the ages of 18-55 years;&#xD;
&#xD;
        -  Participants will be apparently healthy and free from disease, as determined by a health&#xD;
           history questionnaire;&#xD;
&#xD;
        -  Participants will not be excluded if he or she has been clinically diagnosed with a&#xD;
           carbohydrate malabsorption disorder, or is or has been prescribed to take prescription&#xD;
           or over-the-counter medication for such;&#xD;
&#xD;
        -  Participant has self-diagnosed or otherwise avoids consuming dairy, lactose, and other&#xD;
           dairy-containing products, or regularly consumes Lactase enzymes for digestive support;&#xD;
&#xD;
        -  Participant agrees and can comply with the study protocol;&#xD;
&#xD;
        -  Participant provides signed and dated informed consent to participate in the study.&#xD;
&#xD;
      Subject Exclusion Criteria&#xD;
&#xD;
        -  Participant is or may be pregnant, is trying to become pregnant, or is breastfeeding;&#xD;
&#xD;
        -  Participant is insulin-dependent or -independent diabetic.&#xD;
&#xD;
        -  Participant currently uses, or has discontinued the use of nicotine-containing products&#xD;
           within twelve (12) months of the start of the study;&#xD;
&#xD;
        -  Participant lives or works within an environment that chronically exposes the subject to&#xD;
           second-hand smoke;&#xD;
&#xD;
        -  Participant currently uses, or has discontinued the use of recreational drugs or&#xD;
           medicinal marijuana within twelve (12) months of the start of the study;&#xD;
&#xD;
        -  Participant has been clinically diagnosed with a digestive disorder such as&#xD;
           gastrointestinal disease, chronic diarrhea or constipation, irritable or inflammatory&#xD;
           bowel syndrome, Crohn's disease, or is, or has been prescribed to take prescription or&#xD;
           over-the-counter medication for such;&#xD;
&#xD;
        -  Participant has ever undergone gastric bypass surgery, or has undergone an abdominal or&#xD;
           other gastrointestinal surgery within twelve (12) months of the start of the study;&#xD;
&#xD;
        -  Participant is taking, or has taken antibiotic medications within two (2) weeks of the&#xD;
           start of the study;&#xD;
&#xD;
        -  Participant has undergone a colonoscopy within two (2) weeks of the start of the study,&#xD;
           or is scheduled to receive a colonoscopy during the study;&#xD;
&#xD;
        -  Participant has undergone a barium study or received an enema within two (2) weeks of&#xD;
           the start of the study, or is scheduled to, or receives such during the study;&#xD;
&#xD;
        -  Participant is taking, or has taken probiotics within two (2) weeks of the start of the&#xD;
           study;&#xD;
&#xD;
        -  Participant uses lactose digesting enzymes during the study;&#xD;
&#xD;
        -  Participant is taking, or has taken weight loss, prebiotic [e.g., fructo- or&#xD;
           galacto-oligosaccharides (FOS or GOS), psyllium, or insulin fiber, etc.], or laxative /&#xD;
           stool softener dietary supplements, over-the-counter, or prescription medications within&#xD;
           two (2) weeks of the start of the study;&#xD;
&#xD;
        -  Participant is allergic to any ingredient present within the dietary supplement or&#xD;
           placebo treatment;&#xD;
&#xD;
        -  Participant reports any unusual adverse events associated with this study that, in&#xD;
           consultation with the study investigators or the participant's doctor recommends removal&#xD;
           from the body;&#xD;
&#xD;
        -  Participant fails to comply with the study protocol.&#xD;
&#xD;
      Intervention Below is an overview of the study, including the phases, timepoints, and&#xD;
      dependent variables that will be assessed. The total study duration for each subject is&#xD;
      approximately fifteen (15) weeks - one (1) week of pre-test familiarization plus fourteen&#xD;
      (14) weeks of intervention and testing. Subject testing will commence on a rolling enrollment&#xD;
      basis (i.e., all subjects will not start, be tested on, and end the study at the same time).&#xD;
&#xD;
      24 hrs - 12 hrs: Restricted Diet&#xD;
&#xD;
      Discontinue eating:&#xD;
&#xD;
        -  All grains (including pasta, bread, cereals)&#xD;
&#xD;
        -  Fruits&#xD;
&#xD;
        -  Vegetables (including any food products that contain corn, corn starch, etc)&#xD;
&#xD;
        -  Nuts and seeds&#xD;
&#xD;
        -  Beans/ Legumes&#xD;
&#xD;
        -  All dairy products (including cheese, ice cream, butter, and yogurt)&#xD;
&#xD;
        -  All meats [except those approved (below)]&#xD;
&#xD;
      Allowed foods:&#xD;
&#xD;
        -  Baked or broiled chicken, fish or turkey (salt and pepper seasoning only)&#xD;
&#xD;
        -  Plain, steamed white rice&#xD;
&#xD;
        -  Eggs&#xD;
&#xD;
        -  Clear chicken or beef broth&#xD;
&#xD;
        -  White bread (only)&#xD;
&#xD;
        -  Participants may drink water, coffee, or tea; no sugar or artificial sweetener; no&#xD;
           creamer/cream 12 hrs - 0 hrs: Fasting&#xD;
&#xD;
        -  Water only&#xD;
&#xD;
        -  No sleeping or vigorous exercise for at least (1) hour prior to any time during the&#xD;
           breath test&#xD;
&#xD;
      TIMELINE:&#xD;
&#xD;
      Day -7 - 0 - Pre-screening &amp; Familiarization&#xD;
&#xD;
        -  Subjects complete one-week nutrition log via MyFitnessPal Day 0 - Baseline &amp; Acute&#xD;
           Response (Lab Test #1; LT1)&#xD;
&#xD;
        -  Subject arrives 12-hr fasted (water only) and having followed the 24hr pre-test and&#xD;
           lifestyle protocol -&gt; Body Mass (BM) and Hydration (urine) measurements -&gt; 5-minute&#xD;
           seated -&gt; Heartrate (HR) and Blood Pressure (BP) measurements -&gt; Gastrointestinal&#xD;
           Symptom Score -&gt; Venous Blood collection -&gt; Non-Alcohol Mouth Rinse -&gt; Breath Analysis&#xD;
           -&gt; Treatment Dose Consumed with 8-10 fl. oz. H2O -&gt; 30- minute seated -&gt; 25-gram Lactose&#xD;
           Challenge/Ingestion -&gt; 60- minute seated -&gt; Non-Alcohol Mouth Rinse -&gt; Breath Analysis&#xD;
           -&gt; 60-minute seated -&gt; Non-Alcohol Mouth Rinse -&gt; Breath Analysis -&gt; 60 minute seated -&gt;&#xD;
           Gastrointestinal Symptoms Score -&gt; Non-Alcohol Mouth Rinse -&gt; Breath Analysis Day 1 -&#xD;
           Day 7 - Treatment Phase&#xD;
&#xD;
        -  Subjects consume three (3) servings per day of treatment at scheduled times and&#xD;
           conditions for three (3) days -&gt; On Day 4 subjects perform a Lactose Challenge /&#xD;
           Ingestion Test at home after a12-hr fast (water only); Gastrointestinal Symptoms Score&#xD;
           is collected prior to, and at 180 minutes postprandial (after lactose ingestion) -&gt;&#xD;
           Subjects continue to consume three (3) servings per day of treatment at scheduled times&#xD;
           and conditions for three (3) days&#xD;
&#xD;
        -  Subjects complete one-week nutrition log Day 7 - Subacute Response (Lab Test #2; LT2)&#xD;
&#xD;
        -  Repeat LT1&#xD;
&#xD;
        -  Subjects discontinue treatment Day 8 - Day 37 - 30- Day Post Treatment Phase&#xD;
&#xD;
        -  Subjects perform weekly Lactose Challenge/Ingestion Testing at home with&#xD;
           Gastrointestinal Symptoms Scoring&#xD;
&#xD;
        -  Subjects complete one-week nutrition logs Day 37 - 30-Day Post Treatment Response (Lab&#xD;
           Test #3; LT3)&#xD;
&#xD;
        -  Repeat LT1/LT2 testing (less the Treatment Dose + 30-minute seating pre-Lactose&#xD;
           Challenge / Ingestion) Day 38 - Day 67 - 60-Day Post Treatment Phase&#xD;
&#xD;
        -  Subjects perform weekly Lactose Challenge/Ingestion Testing at home with&#xD;
           Gastrointestinal Symptoms scoring&#xD;
&#xD;
        -  Subjects complete one-week nutrition logs Day 67 - 60- Day Post Treatment Response (Lab&#xD;
           Test #4; LT4)&#xD;
&#xD;
        -  Repeat LT1/LT2/LT3 testing (less treatment Dose + 30-minute seated pre- Lactose&#xD;
           Challenge/Ingestion) Day 68 - Day 97 - 90-Day Treatment Phase&#xD;
&#xD;
        -  Subjects perform weekly Lactose Challenge/Ingestion Testing at home with&#xD;
           Gastrointestinal Symptoms Scoring&#xD;
&#xD;
        -  Subjects complete one-week nutrition logs Day 97 - 90-Day Post Treatment Response (Lab&#xD;
           Test #5; LT5)&#xD;
&#xD;
        -  Repeat LT1/LT2/LT3/LT4/ testing (less Treatment Dose + 30- minute seating pre- Lactose&#xD;
           Challenge/ Ingestion)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Anticipated">August 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 25, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>3 treatments: low dose probiotic, high dose probiotic, placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lactobacillus Acidophilus MPH734's Effect on lactose digestion in individuals who identify as lactose sensitive, intolerant, or avoid dairy.</measure>
    <time_frame>97 days</time_frame>
    <description>Primary outcome of this study is to determine if twice or three times daily supplementation of Lactobacillus acidophilus MPH734 (Lacto-FreedomTM, or LF), for one week, affects acute (immediate), subacute (7 days), and post-treatment discontinuation (30-, 60-, and 90- day) lactose metabolism, gastrointestinal symptoms, and clinical markers of inflammation and safety compared to a placebo.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Lactose Intolerance</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose 10 billion CFU per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose 15 billion CFU per day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Taken once prior to the first testing session, 3x a day every day for the 7 days of supplementation, and taken one last time during second testing session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus acidophilus MPH734</intervention_name>
    <description>After supplementing with oral probiotics, it has been suggested that select probiotics capable of expressing Beta-glucosidase enzyme activity may likewise be effective treatment for lactose intolerance.</description>
    <arm_group_label>High dose 15 billion CFU per day</arm_group_label>
    <arm_group_label>Low dose 10 billion CFU per day</arm_group_label>
    <other_name>Lacto-FreedomTM, or LF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo made to match dietary supplement being tested.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants will be male or female between the ages of 18-55 years;&#xD;
&#xD;
          -  Participants will be apparently healthy and free from disease, as determined by a&#xD;
             health history questionnaire;&#xD;
&#xD;
          -  Participants will not be excluded if he or she has been clinically diagnosed with a&#xD;
             carbohydrate malabsorption disorder, or is or has been prescribed to take prescription&#xD;
             or over-the-counter medication for such;&#xD;
&#xD;
          -  Participant has self-diagnosed or otherwise avoids consuming dairy, lactose, and other&#xD;
             dairy-containing products, or regularly consumes Lactase enzymes for digestive&#xD;
             support;&#xD;
&#xD;
          -  Participant agrees and can comply with the study protocol;&#xD;
&#xD;
          -  Participant provides signed and dated informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant is or may be pregnant, is trying to become pregnant, or is breastfeeding;&#xD;
&#xD;
          -  Participant currently uses, or has discontinued the use of nicotine-containing&#xD;
             products within twelve (12) months of the start of the study;&#xD;
&#xD;
          -  Participant lives or works within an environment that chronically exposes the subject&#xD;
             to second-hand smoke;&#xD;
&#xD;
          -  Participant currently uses, or has discontinued the use of recreational drugs or&#xD;
             medicinal marijuana within twelve (12) months of the start of the study;&#xD;
&#xD;
          -  Participant has been clinically diagnosed with a digestive disorder such as&#xD;
             gastrointestinal disease, chronic diarrhea or constipation, irritable or inflammatory&#xD;
             bowel syndrome, Crohn's disease, or is, or has been prescribed to take prescription or&#xD;
             over-the-counter medication for such;&#xD;
&#xD;
          -  Participant has ever undergone gastric bypass surgery, or has undergone an abdominal&#xD;
             or other gastrointestinal surgery within twelve (12) months of the start of the study;&#xD;
&#xD;
          -  Participant is taking, or has taken antibiotic medications within two (2) weeks of the&#xD;
             start of the study;&#xD;
&#xD;
          -  Participant has undergone a colonoscopy within two (2) weeks of the start of the&#xD;
             study, or is scheduled to receive a colonoscopy during the study;&#xD;
&#xD;
          -  Participant has undergone a barium study or received an enema within two (2) weeks of&#xD;
             the start of the study, or is scheduled to, or receives such during the study;&#xD;
&#xD;
          -  Participant is taking, or has taken probiotics within two (2) weeks of the start of&#xD;
             the study;&#xD;
&#xD;
          -  Participant uses lactose digesting enzymes during the study;&#xD;
&#xD;
          -  Participant is taking, or has taken weight loss, prebiotic [e.g., fructo- or&#xD;
             galacto-oligosaccharides (FOS or GOS), psyllium, or insulin fiber, etc.], or laxative&#xD;
             / stool softener dietary supplements, over-the-counter, or prescription medications&#xD;
             within two (2) weeks of the start of the study;&#xD;
&#xD;
          -  Participant is allergic to any ingredient present within the dietary supplement or&#xD;
             placebo treatment;&#xD;
&#xD;
          -  Participant reports any unusual adverse events associated with this study that, in&#xD;
             consultation with the study investigators or the participant's doctor recommends&#xD;
             removal from the study;&#xD;
&#xD;
          -  Participant fails to comply with the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Mary Hardin-Baylor</name>
      <address>
        <city>Belton</city>
        <state>Texas</state>
        <zip>76513</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Tinnin, MS</last_name>
      <phone>254-295-5569</phone>
      <email>mtinnin@umhb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Prather, BS</last_name>
      <phone>254-295-5571</phone>
      <email>jprather@mail.umhb.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Mary Hardin-Baylor</investigator_affiliation>
    <investigator_full_name>Lemuel W. Taylor IV</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>lactose intolerance</keyword>
  <keyword>probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactose Intolerance</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

